etoposide oral / Generic mfg. - LARVOL DELTA

Combination Therapy for Platinum-Resistant Ovarian Cancer: A Novel At-Home Regimen with Envafolimab, Lenvatinib, and Etoposide. (PubMed, Oncologist) - P2 | "Envafolimab combined with lenvatinib and etoposide showed promising efficacy and tolerable safety for patients with platinum-resistant recurrent ovarian cancer."

Journal • Platinum resistant • CNS Disorders • Depression • Hematological Disorders • Leukopenia • Mood Disorders • Oncology • Ovarian Cancer • Psychiatry • Solid Tumor • Thrombocytopenia

Adjuvant Etoposide for Very High-Risk PFA Ependymoma: A Case Report. (PubMed, J Pediatr Hematol Oncol) - "This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial."

Journal • Cardiovascular • CNS Disorders • Ependymoma • Hypertension • Oncology • Solid Tumor • Ventriculomegaly

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Not yet recruiting | Sponsor: Indiana University | Initiation date: Apr 2025 ➔ Jul 2025

Trial initiation date • Germ Cell Tumors

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors. (ASCO 2025) - P2 | "Treatment consisted of continuous sirolimus (2 mg/m2/dose PO daily), celecoxib (100 mg PO BID), and oral etoposide (50 mg/m2/day; max: 100 mg) alternating every 21 days with oral cyclophosphamide (2.5 mg/kg/day; max: 100 mg) in 42-day cycles. The combination of sirolimus with metronomic chemotherapy showed limited activity in patients with R/R solid tumors, although prolonged disease stabilization was seen across multiple histologies consistent with a metronomic approach."

Clinical • Combination therapy • P2 data • Brain Cancer • CNS Tumor • Ewing Sarcoma • Gastrointestinal Disorder • Nephrology • Neuroblastoma • Oncology • Osteosarcoma • Pediatrics • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Wilms Tumor

Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov) - P1/2 | N=38 | Not yet recruiting | Sponsor: Indiana University

New P1/2 trial • Germ Cell Tumors

FUS Etoposide for DMG (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Columbia University | Suspended ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Aumolertinib in combination with Lastet in the first-line treatment of EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (EVOLUTION): protocol for a single-arm, phase II clinical trial. (PubMed, BMJ Open) - P2 | "The results of the study will be disseminated through peer-reviewed journals and presentations at academic conferences. NCT06463171."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • EGFR

Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study. (PubMed, Int J Gynecol Cancer) - P2 | "Niraparib combined with etoposide showed evidence of antitumor activity in platinum resistant/refractory ovarian cancer after ≤2 lines of platinum based chemotherapy, particularly in patients with a BRCA mutation, homologous recombination deficiency, or primary platinum resistance. This once-a-day oral combination was a convenient option."

Journal • P2 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • BRCA • HRD

TUC-TOC: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Institut Curie | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: City of Hope Medical Center | Active, not recruiting ➔ Completed

Trial completion • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Hematological Malignancies • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK • CD34

Persistence of Cutibacterium acnes for Nine Years in a Host With a Cranial Implant (AAN 2025) - "While chronic meningitis is often immune-mediated, indolent infections remain a key consideration in the differential diagnosis.Design/N/AA 43-year-old man with history of a recurrent 4th ventricular anaplastic ependymoma requiring three resections between 1996 and 2010, radiation therapy, and years of oral low-dose etoposide chemotherapy, developed nine years of recurrent headaches...His positive response to steroids was attributed to an immune-mediated process, prompting initiation of oral methotrexate (MTX) as a steroid-sparing agent...A high index of suspicion for chronic infections, including C. acnes and other biofilm-forming bacteria, is essential in patients with cranial implants, along with the need for cultures obtained near the implants to definitively confirm infection."

CNS Disorders • Ependymoma • Immunology • Infectious Disease • Oncology • Pain • Respiratory Diseases • Solid Tumor

Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia. (ASCO-GU 2025) - "Of the 22 patients, 3 (14%) had pure seminoma, 3 (14%) had primary mediastinal non-seminoma (PMNSGCT), 10 (45%) patients had cisplatin resistant disease, 7 (32%) and 15 (68%) of patients received 1 and 2 cycles of HDCT, respectively, 5 (23%) received maintenance oral etoposide and 6 (27%) had post-HDCT surgery...Of 22 patients, 3 have received single dose CarboPEC (carboplatin, etoposide, cyclophosphamide) regimen in 2014 and 2015... HDCT is an effective salvage option in heavily pretreated relapsed GCTs. Our study suffers from weakness associated with small number of patients and selection biases. However, increasing expertise and timely delivery of HDCT results in cures in relapsed GCTs including cisplatin resistant subgroup."

Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Cancer • Testicular Seminoma

Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ cell tumors (GCT) undergoing palliative chemotherapy (CT) in the United States (US). (ASCO-GU 2025) - "Index regimens included gemcitabine-oxaliplatin (47.5%), oral etoposide (13.8%), gemcitabine-paclitaxel (13.8%), and gemcitabine-oxaliplatin-paclitaxel (7.5%). This study is the first to use rw proxies for PD in claims data to estimate TTrwP in pts with R/R testicular GCT. With no curable treatment options remaining, the short TTrwP highlights the poor outcomes in this patient population and need for novel therapies to improve clinical outcomes. RW PD events observed in pts with R/R GCT (N=80)."

Clinical • Real-world • Real-world evidence • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Cancer

The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data. (PubMed, Medicine (Baltimore)) - "This study aims to evaluate the efficacy and safety of weekly paclitaxel or oral etoposide as second-line treatments for classical and iatrogenic Kaposi sarcoma. Given the high ORR and DCR, these therapies represent viable options for patients who progress after initial treatment. Further studies with larger patient populations are needed to confirm these findings."

Journal • Real-world evidence • Retrospective data • Epstein-Barr Virus Infections • Febrile Neutropenia • Infectious Disease • Kaposi Sarcoma • Neutropenia • Pain • Sarcoma • Solid Tumor

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2024 ➔ Oct 2025 | Trial primary completion date: Dec 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD34

Efficacy and Safety of Low-Dose Oral Etoposide Combined With Capecitabine for Patients With Postoperative Metastatic Breast Cancer Resistant to Anthracycline/Taxanes. (PubMed, Thorac Cancer) - "For patients with postoperative MBC resistant to anthracycline/taxanes, oral low-dose etoposide + capecitabine was effective with tolerable safety. The patients did not need antiemetics or leukocytic drugs, and the treatment was cost-effective because the patients did not need to be hospitalized for intravenous infusion."

Journal • Breast Cancer • Fatigue • Hematological Disorders • Leukopenia • Oncology • Solid Tumor

FUS Etoposide for DMG (clinicaltrials.gov) - P1 | N=10 | Suspended | Sponsor: Columbia University | Trial completion date: Jan 2027 ➔ Dec 2027 | Active, not recruiting ➔ Suspended | Trial primary completion date: Jan 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Trial suspension • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients. (PubMed, Sarcoma) - "The median PFS was 3.6 months (95% CI: 1.7-5.5), and OS was 8.5 months (95% CI: 4.1-13.0). Despite prior exposure, oral etoposide demonstrated antitumour activity and durable responses in the relapsed or refractory setting for adult patients with Ewing sarcoma."

Journal • Ewing Sarcoma • Oncology • Pediatrics • Sarcoma • Solid Tumor

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Nabil Adra | Trial completion date: Dec 2029 ➔ Dec 2028

Trial completion date • Germ Cell Tumors • Oncology • Ovarian Cancer • Solid Tumor

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Nabil Adra | Trial completion date: Dec 2028 ➔ Dec 2029

Metastases • Trial completion date • Germ Cell Tumors • Oncology • Ovarian Cancer • Solid Tumor

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. (PubMed, BMC Cancer) - P2 | "The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity."

Journal • Metastases • P2 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Solid Tumor • HER-2

A PHASE I TRIAL AND PHARMACOKINETIC STUDY OF ORAL HDAC INHIBITOR CHIDAMIDE COMBINED WITH ETOPOSIDE IN CHILDREN WITH REFRACTORY/RECURRENT NEUROBLASTOMA. (SIOP 2024) - "In children with refractory/recurrent neuroblastoma, chidamide is well-tolerabled at 14 mg/m2/d twice weekly when combining with oral etoposide 35 mg/m2/d daily. Prolonged disease stability achieved in patients with minimal residual diseases or only residual bone lesions deserves further investigation."

Clinical • P1 data • PK/PD data • Anemia • CNS Tumor • Hematological Disorders • Hematological Malignancies • Neuroblastoma • Neutropenia • Oncology • Pediatrics • Solid Tumor • Thrombocytopenia

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor: Beijing Sanbo Brain Hospital | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Brain Cancer • Medulloblastoma • Oncology • Solid Tumor

Overall Experience of Two Clinical Trials for FUS-Mediated Blood Brain Barrier-Opening for Patients with DIPG/DMG Delivered in Radiation Oncology (ASTRO 2024) - P1 | "Materials/ Pediatric and AYA patients with biopsy proven DIPG/DMG at disease relapsed were enrolled onto clinicaltrial.org identified NCT04804709 (FUS with oral panobinostat) or clinicaltrial.org identified NCT05762419 (FUS with oral etoposide). FUS-mediated BBB-opening delivered as an outpatient procedure is preliminarily feasible in children with relapsed DIPG/DMG. Further studies are needed to assess for efficacy."

Clinical • Brain Cancer • Dermatology • Oncology • Pediatrics • Solid Tumor

Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study (ESMO 2024) - P2 | "The current single-arm prospective phase II study aimed to evaluate the efficacy and safety of pyrotinib in combination with metronomic oral etoposide in heavily pretreated HER2-positive MBC. Eligible HER2-positive MBC patients previously treated with trastuzumab were enrolled to receive oral pyrotinib 400mg per day and metronomic oral etoposide 50mg per day d1-21 every 28 days, until disease progression or unacceptable toxicity. The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity. Our findings provide an alternative treatment option for the later-line treatment of HER-positive MBC, which worth further investigation."

Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2